Disappearance of Allergic Reaction to Cromolyn (Cromoglycate) By Avoidance and Then Reintroduction

Abstract

Cromolyn or cromoglycate sodium (DSCG) is a primary therapy of asthma. A most important aspect of DSCG use is that significant adverse events are rare. DSCG is also available in the United States in forms for nasal, ocular, and gastrointestinal administration. There are three formulations of DSCG for treating asthma, nebulizer solution, metered dose inhaler, and powder for the spinhaler. The availability of these additional uses and forms, has increased exposure to DSCG. There has been no corresponding increase in reports of adverse reactions.